Other Events ·
Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, indicating it no longer meets the minimum…
JSPRWJasper Therapeutics, Inc.
Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, indicating it no longer meets the minimum stockholders' equity requirement of $2.5 million for continued listing under Listing Rule 5550(b)(1). The company has until October 5, 2026, to submit a compliance plan and anticipates regaining compliance through stockholder approval of converting its Non-Voting Convertible Preferred Stock at an upcoming special meeting. Failure to regain compliance could lead to delisting proceedings before Nasdaq's Hearing Panel. Jasper Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.